Welcome!

News Feed Item

The Leukemia & Lymphoma Society Announces Recipients of The Screen to Lead Grant Program

Five Distinguished Researchers Receive First-Time Grant

WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers.  

LLS recognizes investigators' significant need for resources to develop small molecules into drug-like compounds suitable for preclinical proof-of-concept testing in cancer models.  The goal is to fill a gap in the drug development process in academic laboratories, with the potential that novel targeted therapies may eventually be evaluated and benefit patients.

"LLS funds research to advance more breakthrough therapies for cancer patients.  This funding support is specifically designed to advance promising compounds in the earliest stages of development," said Lee Greenberger, Ph.D., LLS chief scientific officer.  "It is critically important that leading scientists and researchers get financial resources to pursue innovative, novel approaches that can change the standard of care for patients with blood cancers."

The amounts of the grants awarded to these innovative researchers will vary and be determined on a case by case basis. The awardees are:

Li Chai, M.D. – Brigham and Women's, Boston
Chai will target SALL4 in the treatment of acute myeloid leukemia (AML).  SALL4 is a transcription factor – a protein that regulates genetic activity, and is abnormally expressed in most AML patient samples.  Chai's team has been testing a peptide that can block SALL4.  While peptides can be useful as tools, they have low stability in the body so the team is performing high throughput tests to identify other compounds with drug-like characteristics that might also be effective in blocking SALL4. The team has produced an assay, a laboratory test that enables researchers to examine thousands of compounds, that will be used by a contract research organization (CRO) to identify those that are effective against SALL4.

Michael Deininger, M.D., Ph.D. – Huntsman Cancer Institute, Salt Lake City
Signal Transducer and Activator of Transcription 3 (STAT3) is a protein involved in the regulation of cell growth and survival.  It is frequently super-activated in patients with certain cancers.  Deininger has developed assays to identify STAT3 inhibitors and through medicinal chemistry approaches, has generated more potent inhibitors.  The grant will assist him in his goal of making compounds more effective at inhibiting STAT3 at lower doses.  Promising compounds will be synthesized on a larger scale and will be tested in animal models of therapy-resistant chronic myeloid leukemia (CML) as well as in myelofibrosis (MF).  Since STAT3 is activated in a number of cancers, compounds developed may be useful beyond CML and MF.

Yali Dou, Ph.D. – University of Michigan
Epigenetics are small chemical modifications that alter gene activity without changing the DNA code of those genes.  Abnormal epigenetic changes are often associated with the growth of cancer cells.  A protein known as mixed-lineage leukemia protein (MLL) works with a host of other proteins to mediate such epigenetic alterations and is genetically altered in certain patients with AML resulting in a particularly poor prognosis for these patients.  Dou's team has developed an assay whereby purified MLL and its associated co-regulator proteins are mixed, and their epigenetic modifying activity can be quantitatively measured.  They will screen large libraries of compounds with drug-like characteristics in this assay, and determine which ones can inhibit the epigenetic modifying activity.  Positive hits in the screen will be used as lead compounds for improvement, which can then be tested in cancer models as antitumor agents.

Aaron Schimmer, M.D., Ph.D. – Princess Margaret Cancer Center/Ontario Cancer Institute
The proteasome is a machine in the cell that regulates the degradation of proteins in the cells, and is essential to getting rid of proteins no longer needed.  In addition, the proteasome is crucial to the normal cell signaling process required for growth and survival of the cell.  Certain cancer cells, such as those found in patients with multiple myeloma, have high levels of proteasome activity.  Thus, inhibiting the proteasome has been an effective anti-cancer therapy, as is the case of Velcade® in patients with multiple myeloma.  Velcade targets the proteasome in the cytoplasm.  Schimmer has recently shown that inhibiting the proteasome in the mitochondria (energy factory) has anti-tumor activity.  This is a novel approach to cancer therapy, and the identification of a drug specifically targeting the mitochondrial proteasome may lead to a first-in-class drug for treatment of patients with AML and potentially other cancers.

David Williams, M.D. – Children's Hospital Boston
The Rac proteins are required for cancer development in a number of systems.  Williams has explored the role of these proteins in CML, AML, and more recently, acute lymphocytic leukemia (ALL).  His team has shown that inhibition of Rac can lead to cancer cell death.  From previously LLS-funded research, compounds were identified that inhibit Rac and were tested as anti-cancer agents.  They successfully identified a number of lead compounds worthy of further refinement.  The purpose of this grant is to continue the project to use a medicinal chemistry approach to improve these compounds, potentially identifying lead compounds that may be candidates for clinical evaluation. 

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
[email protected]

SOURCE The Leukemia & Lymphoma Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
SYS-CON Events announced today that SkyScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SkyScale is a world-class provider of cloud-based, ultra-fast multi-GPU hardware platforms for lease to customers desiring the fastest performance available as a service anywhere in the world. SkyScale builds, configures, and manages dedicated systems strategically located in maximum-security...